Hans Fredrik Mattsson

Président chez Celemi International AB Fortune : 183 177 $ au 30/06/2026

Profil

Hans Fredrik Mattsson currently works at Celemi International AB, as Chairman, Dipylon Medical AB, as Director, Investment AB Bure, as Director, and Bure Growth AB, as Director.
Mr. Mattsson also formerly worked at Vittra Utbildning AB, as Chief Executive Officer, Anew Learning AB, as Chief Executive Officer, Xvivo Perfusion AB, as Chairman from 2012 to 2018, BioLamina AB, as Chairman, Bure Equity AB, as Investment Director from 2009 to 2018, Vitrolife AB, as Independent Director from 2007 to 2018, Mercuri International Group AB, as Director, MedCap AB, as Director, Bure Equity, as Investment Director from 2010 to 2018, Energo-Retea AB, as Director, Celemiab Group AB, as Director, Theducation AB, as Director, Life Genomics AB, as Director, Devyser Diagnostics AB, as Independent Director, Skanditek Industriförvaltning AB, as Principal, Gambro Renal Products, Inc., as Vice President-Homecare, and McKinsey & Co. Service AB, as Management Consultant.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
MEDCAP AB 0,02%	31/12/2025	3 380 ( 0,02% )	183 177 $	30/06/2026

Postes actifs de Hans Fredrik Mattsson

Sociétés	Poste	Début
Dipylon Medical AB	Directeur/Membre du Conseil	-
Investment AB Bure	Directeur/Membre du Conseil	-
Bure Growth AB	Directeur/Membre du Conseil	-
Celemi International AB	Président	-

Anciens postes connus de Hans Fredrik Mattsson

Sociétés	Poste	Fin
Bure Equity (Private Equity)	Private Equity Investor	31/10/2018
BURE EQUITY AB	Directeur en chef des Investissements	15/09/2018
XVIVO PERFUSION AB	Président	27/04/2018
Energo-Retea AB	Directeur/Membre du Conseil	26/12/2012
Skanditek Industriförvaltning AB	Corporate Officer/Principal	21/06/2011